Vir Biotechnology (VIR) Shares Outstanding (Weighted Average) (2018 - 2026)

Vir Biotechnology has disclosed Shares Outstanding (Weighted Average) across 9 years of filings, most recently posting $147.4 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $147.4 million, up 7.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $147.4 million (up 7.19% YoY), and the FY2025 annual result was $138.5 million, up 1.67% from the prior year.
• Shares Outstanding (Weighted Average) came in at $147.4 million for Q1 2026 at Vir Biotechnology, up from $138.5 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $147.4 million in Q1 2026 to a low of $132.1 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $135.3 million (2024), against an average of $135.9 million.
• Across the five-year window, Shares Outstanding (Weighted Average) climbed 0.93% in 2023 and gained 7.19% in 2026, its largest moves.
• Vir Biotechnology's Shares Outstanding (Weighted Average) stood at $132.6 million in 2022, then climbed by 1.15% to $134.1 million in 2023, then climbed by 1.58% to $136.2 million in 2024, then gained by 1.67% to $138.5 million in 2025, then rose by 6.38% to $147.4 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $147.4 million (Q1 2026), $138.5 million (Q4 2025), and $138.9 million (Q3 2025), per Business Quant data.